Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H. pylori Eradication in Iraqi ITP Patients
NCT07150286Completed
- Sponsor
- Al-Mustansiriyah University
- Start
- Sep 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of levofloxacin in immune thrombocytopenia (ITP) and Helicobacter pylori infection (2 arms), sponsored by Al-Mustansiriyah University. Primary endpoint: Change in Platelet Count After H. pylori Eradication. Started Sep 2024; status: completed.
02
Drugs
levofloxacin
03
Conditions
immune thrombocytopenia (ITP)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07150286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150286.